User: Guest

  



DOMAIN EXPERT ENGAGEMENTS

Number of executives repeatedly engaged by snail & email outreach*

POOL + OUTREACH

7288

Interactions with Platform & by Email *

INTERACTIONS

1020

Unique # Participated *

PARTICIPANTS

219

Responses Validated *

VALIDATIONS

41

* Platform engagements are dynamic. Stats are published quarterly.


  •  CODE

  •  PAGES

  •  DATE

  •  PRICE

    $

  •  DATA EXHIBITS

    125


TABLE OF CONTENTS


   Pages :    | $

   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2
Data Interpretation & Reporting Level.....I-2
  
   Quantitative Techniques & Analytics.....I-3
Product Definitions and Scope of Study.....I-3
  
   A Prelude.....II-1
Protein Drugs Are the Best Sellers.....II-1
1$100
   Key Statistics:.....II-2
Table 1: World Market for Biopharmaceuticals (2009): Top 10 Brands Ranked by Dollar Sales (In US$ Billion) (includes corresponding Graph/Chart).....II-2

Table 2: World Market for Biopharmaceuticals (2007 & 2008): Top 15 Brands Ranked by Dollar Sales (In US$ Billion).....II-2
1$350
   Competitive Scenario.....II-3
Intensifying Consolidation Activity.....II-3
1$100
   Impact of Recession: A Review.....II-4
Impact of Recession on Drug Sales.....II-4
Impact of Recession on R&D Activities.....II-4
Not Recession, But Generic Competition Will Cause Sales Erosion.....II-4
Patent Expiration.....II-4
1$100
   Impending Patent Expiry For Key Protein Drugs.....II-5
Patent Expirations For Key Protein and Peptide Drugs in the Recent Past.....II-5
Follow-on Biologics: An Opportunity in Adverse Conditions.....II-5
1$100
   Legal and Scientific Viability of Follow-on Protein Drugs.....II-6
MAb: A Market Better Protected from Generic Competition.....II-6
Approved Monoclonal Antibodies in the Market.....II-6
1$100
   Unmet Medical Needs in Emerging Markets Provides Fertile Environment.....II-7
Key Market Trends & Issues: A Review.....II-7
Continuous Fight Against Diseases: A Key Propeller for Growth.....II-7
1$100
   Population Aging Makes Rise Of Protein Drugs Inevitable.....II-8
Ability to Address Wide Gamut of Diseases is Key to Success.....II-8
Combination Biologics Can Offer New Treatment Possibilities.....II-8
1$100
   Shift Towards Humanized and Fully Human Antibodies.....II-9
Biotechnology Gives a New Direction.....II-9
Innovative Drug Delivery Methods: The Need of the Hour.....II-9
1$100
   Companies Seek Partnerships and Collaborations to Sustain Profit Margins.....II-10
Increasing Demand for Protein A in Mab Manufacturing.....II-10
Rising Number of MAbs Under Clinical Trials.....II-10
1$100
   Major Protein Drugs in Pipeline As of 2009.....II-111$100
   Untapped Pharmacological Potential of GPCRs Ignites Interest.....II-121$100
   Increased Reliance on Contract Manufacturing.....II-13
Reimbursement & Price Sensitivity Are Key Challenges.....II-13
1$100
   Manufacturing Bottleneck.....II-14
High Costs Impede Penetration.....II-14
1$100
   A Special Focus On Key Regional Markets.....II-15
United States.....II-15
Market Overview.....II-15
Biologicals: A Review.....II-15
Biologicals: A Costly Preposition.....II-15
Recombinant Proteins To Continue Their Significance as Key Biologic
  Products.....II-15
1$100
   Recombinant Blood-Related Agents to Continue Their Market Growth.....II-16
Early Generic Competition Will Unsettle Revenues for Key Protein Drugs.....II-16
1$100
   Key Statistics:.....II-17
Table 3: US Market for Protein Therapeutics (2010): Percentage Share Breakdown of Dollar Sales for Key Therapy Area (includes corresponding Graph/Chart).....II-17
China.....II-17
Market Overview.....II-17
China to Emerge As Biosimilar Major.....II-17
1$350
   Lack of Regulatory Framework.....II-18
India.....II-18
Market Overview.....II-18
Indian Pharma Companies Gear Up to Grab a Big Slice of Global Follow-On Biologics
  Market.....II-18
Openness in US Market Will Provide Opportunities.....II-18
2$200
   An Introduction.....II-20
Structural Information.....II-20
1$100
   Classification of Proteins.....II-21
Sources of Protein Drugs.....II-21
Types of Protein-Based Drugs.....II-21
Cytokines.....II-21
1$100
   Clotting factors.....II-22
Hormones.....II-22
Monoclonal Antibodies (Mabs).....II-22
Vaccines.....II-22
Different Types of Protein Drugs.....II-22
1$100
   Applications.....II-23
Significance of Biotechnology in Protein-Based Drugs.....II-23
Hybridoma Cell Technology.....II-23
Recombinant DNA Technology.....II-23
Production of Protein Drugs through Transgenic Animals.....II-23
1$100
   Disadvantages of Protein-based Drugs.....II-24
Immunogenicity of Protein-Based Drugs.....II-24
1$100
   Millipore Launches Magna RIPTM RNA-binding ProteinImmunoprecipitation Kit.....II-25
Millipore Unveils AllostericProfilerTM Service.....II-25
Caliper Life Sciences Introduces Two Products to Expand LabChip GX Product
  Range.....II-25
1$100
   BioDtech Introduces EndoPrep.....II-26
Amgen Introduces Vectibix.....II-26
Trevigen Introduces Mouse Monoclonal Antibody.....II-26
UCB Receives FDA Approval for Cimzia®.....II-26
1$100
   MD Biosciences Launches Keratocan and Lumican Monoclonal Antibodies.....II-27
PhyNexus Introduces PhyTip® ProPlus™ Columns.....II-27
1$100
   Novartis Vaccines Receives EC Approval for Menveo®.....II-28
Lonza Takes Over Algonomics.....II-28
Daicel Chemical Takes Over ChromTech.....II-28
1$100
   Roche Licenses ProTek Stabilisation Technology of Aegis Therapeutics.....II-29
Lonza to Manufacture Arzerra.....II-29
Sanofi Pasteur Receives FDA Approval for Fluzone® High-Dose Vaccine.....II-29
Maxygen and Astellas Complete Joint Venture Transaction.....II-29
1$100
   Sanofi Pasteur’s Panenza® and Humenza® Vaccines Elicit Strong Immune Response.....II-30
Amgen Collaborates with GSK.....II-30
Nabi Biopharmaceuticals Inks Licensing Agreement with GSK.....II-30
Wyeth Pharmaceuticals and Ambrx Enter into Strategic Alliance.....II-30
1$100
   OPKO Health and Academia Sinica Ink Exclusive License Agreement.....II-31
Seattle Life Sciences and ZymoGenetics Enter into Licensing Pact.....II-31
Roche and Covagen Enter into Collaboration.....II-31
Lonza to Manufacture Biologics for LFB and Medarex.....II-31
1$100
   Protgen Establishes Protein Drug Innovation Center in Beijing.....II-32
National Cheng Kung University Inks MoU with ScinoPharm Taiwan.....II-32
Novo Nordisk and ZymoGenetics Signs Licensing Agreement.....II-32
Lipoxen Signs Collaboration Agreement with Pharmasynthez.....II-32
1$100
   Debiopharm Group Inks License Agreement with Curis.....II-33
Bristol-Myers Squibb Acquires Medarex.....II-33
Sanofi Pasteur Signs Licensing Agreement with Syntiron.....II-33
Sanofi Pasteur Inks Strategic Agreement with ShanH.....II-33
1$100
   Access Pharmaceuticals Acquires Somanta Pharmaceuticals.....II-34
IMUC Completes Molecular Antibody Technology Acquisition.....II-34
Callisto Merger Corporation Merges with Celldex Therapeutics.....II-34
1$100
   Arana and Kyowa Hakko Sign Agreement to Jointly Develop ART 104.....II-35
Eusa Sells Antibody Research Business.....II-35
Dyax and Sanofi-Aventis Sign Agreements.....II-35
1$100
   HGS Enters into Antibody Collaboration Agreement with Xencor.....II-36
Wyeth Pharmaceuticals and Biovitrum Extend ReFacto Supply Agreement.....II-36
Caprotec Bioanalytics and Merck Ink Collaboration Agreement.....II-36
1$100
   Biomonitor Snaps Up Neutekbio.....II-37
GE Healthcare Takes Over MicroCal.....II-37
Arana Therapeutics Enters into Collaboration with Greenovation Biotech.....II-37
1$100
   Bayer Healthcare Acquires Hemophilia Program Assets of Maxygen.....II-38
Sanofi Pasteur Holding Purchases Acambis.....II-38
GlaxoSmithKline Enters into Strategic Alliance with Archemix.....II-38
Talecris Biotherapeutics Inks License Agreement with Crucell.....II-38
1$100
   Polyphor Signs Exclusive Licensing Agreement with Allergan.....II-39
Morphotek® Enters into Partnership with Pivotal BioSciences.....II-39
PharmAthene Snaps Up Biodefence Vaccines Business of Avercia Biologics.....II-39
1$100
   Raven Biotechnologies and CMC ICOS Biologics Ink an Agreement.....II-40
MacroGenics Purchases Raven Biotechnologies.....II-40
1$100
   Abbott Laboratories, Inc. (US).....II-41
Alexion Pharmaceuticals, Inc. (US).....II-41
Amgen, Inc. (US).....II-41
1$100
   Biogen Idec (US).....II-42
Bristol-Myers Squibb Company (US).....II-42
Medarex, Inc. (US).....II-42
1$100
   Crucell N.V. (The Netherlands).....II-43
Dendreon Corporation (US).....II-43
Eli Lilly and Company (US).....II-43
Emergent BioSolutions, Inc. (US).....II-43
1$100
   Genentech, Inc. (US).....II-44
Johnson & Johnson (US).....II-44
Centocor Ortho Biotech, Inc. (US).....II-44
1$100
   MedImmune, Inc. (US).....II-45
Merck Serono S.A. (Switzerland).....II-45
Schering-Plough Corporation (US).....II-45
1$100
   UCB Group (Belgium).....II-46
Unigene Laboratories, Inc. (US).....II-46
Vaccinogen, Inc. (US).....II-46
1$100
   Table 4: World Recent Past, Current & Future Analysis for Protein Drugs by Geographic Region - US and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....II-471$350
   Table 5: World 10-Year Perspective for Protein Drugs by Geographic Region - Percentage Breakdown of Dollar Sales for US and Rest of World Markets for Years 2006, 2009, and 2015 (includes corresponding Graph/Chart).....II-481$350
   Table 6: World Recent Past, Current and Future Analysis for Protein Drugs by Drug Type - Antibodies, Blood Products, Cytokines, Peptide Hormones, Vaccines, and Other Drugs Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....II-491$350
   Table 7: World 10-Year Perspective for Protein Drugs by Drug Type - Percentage Breakdown of Dollar Sales for Antibodies, Blood Products, Cytokines, Peptide Hormones, Vaccines, and Other Drugs for Years 2006, 2009, and 2015 (includes corresponding Graph/Chart).....II-501$350
    
 
 


Sales queries: Sales@StrategyR.com
Research queries: Info411@StrategyR.com